Therapeutic strategies in idiopatic inflammatory myopathies;Stratégies thérapeutiques dans les myopathies inflammatoires

Revue Medicale Suisse

Volumn 5, Issue 199, 2009, Pages 812-818

  Chakour, R ^a   Leimgruber, A ^a   Bart, P A ^a   Spertini, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ATLIZUMAB; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECULIZUMAB; EFALIZUMAB; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; KIOVIG; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; REDIMMUNE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DERMATOMYOSITIS; ELECTROMYOGRAPHY; HUMAN; IDIOPATHIC DISEASE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; POLYMYOSITIS; PRESCRIPTION;

ADOLESCENT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; AZATHIOPRINE; BIOPSY; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; MUSCLES; MYOSITIS; POLYMYOSITIS; PREDNISONE; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 65449146725     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wiendl H. Idiopathic inflammatory myopathies: Current and future therapeutic options. Neurotherapeutics 2008;5:548-57.
2. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002;41:7-13.
3. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: Trial design in aduit idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden.The Netherlands. Neuromuscul Disord 2004; 14:337-45.
4. Hohlfeld R, Dornmair K. Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology 2007;69:1966-7.
5. Datakas MC. Mechanisms of disease: Signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006;2:219-27. Review. Erratum in: Nat Clin Pract Rheumatol 2006;2:398.
6. Authier FJ. Dysimmune and inflammatory myopathies. Rev Prat 2008;58:2253-60.
7. Chérin R Treatment of polymyositis and dermatomyositis. Rev Med Interne 2004;25(Suppl. l):S22-5.
8. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
9. Troyanov Y, Targoff IN,Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies : Analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
10. Benveniste O, Dubourg O, Herson S. New classifications and pathophysiology of the inflammatory myopathies. Rev Med Interne 2007;28:603-12.
11. Targoff IN. Idiopathic inflammatory myopathy: Autoantibody update. Curr Rheumatol Rep 2002;4: 434-41.
12. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-9.
13. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
14. 14Mastaglia FL, Garlepp MJ, Phillips BA, et al. Inflammatory myopathies:Clinical,diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-25.
15. Isenberg DA, Allen E, Farewell V, et al. International myositis and clinical studies group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004; 43:49-54.
16. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
17. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005;4:723-30.
18. Joffe MM, Love LA, Leff RL., et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med I993;94: 379-87.
19. e Ed, 2006.
20. Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumathology 2003;42:1168-72.
21. Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D'Cruz DR Mycophenolate mofetil treatment in resistant myositis. Rheumatology 2007;46:516-8.
22. Rowin J, Amato AA, Deisher N, Cursio J, Meiggioni MN. Mycophenolate mofetil in dermatomyositis: Is it safe? Neurology 2006;66:1245-7.
23. Qushmaq KA, Chalmers A, Esdaile JM. Ciclosporine A in the treatment of refractory adult plymyositis/dermatomyositis: Population based experience in 6 patients and literature review. J Rheumatology 2000;27:2855-9.
24. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CY Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52: 2439-46.
25. Takada K, Nagasaka K, Miyasaka N. Polymyositis/ dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005;38:383-92.
26. Cherin P, Pelletier S. Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-74.
27. Noss EH, Hausner-Sypek DL, Wetnblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis.J Rheumatol 2006;33:1021-6.
28. LevineTD. Rituximab in the treatment of dermatomyositis : An open-label pilot study. Arthritis Rheum 2005;52:601-7.
29. YamasakiY.Yamada H.Yamasaki M,et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/ dermatomyositis. Rheumatology 2007;46:124-30.
30. lannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis:A case series. J Rheumatol 2006;33:1802-4.
31. Hengstman GJ, van den Hoogen FH.van den Engenlen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Long-term follow-up. Euro Neurol 2004;52:61-3.
32. Hollar CB. Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: A pilot study. J Dermatolog Treat 2004;15:35-9.
33. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study. Arch Dermatol 2005;141:855-9.
34. Edge JC, Outland JD, Dempsey JR, Callen JR Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006;142:65-9.